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Exercise-induced during exercise 
testing &considered Moreover, 
EIVT has been considered to ConfB a poor prognosis though this has not 
ken specifml!y studied. Cm a rebospective view of 3869 patients who 
hadundergoneMinecBnicsl exer&etestigbetweenSqMnber1984 
Sspatientswith EIVT.Non-smained 
was defined as ventricular ectopic beats 
nsecutive heals (range 3 to 21 beats). 
sustainedVTwas VT longer than 30 (Deconds or requiring 
intervention. Mea p wss 26 months (range 2 to 58 months). 
Fifty-one patients had nonsuslained VT during exercise testing and only 
ngestive heart failure during the follow-up 
sustained Vi’ during exercise testing, and only 
U seven months after the test. EDIT was 
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tients with M!CM and the 
sudden death. 
HOW REPRODUClBLE E THE RESULTS OF 
ELECTROPHYSIOLOGIC TESTING DURING ANTI 
DRUG THERAPY? 
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Although aLectrophysiologic studies (EPS) are 
commonly used to assess antiarrhythmfc drug (AAD) 
efficacy in pts with ventricular tachycardia(VT), 
the reproducibility of EPS during therapy has not 
bee;? definitively established. We performed 
confirmation studies during AAD therapy in 108 pts 
with sustained VT/VF induced during initial EPS to 
ass:!ss the reproducibility of AAD efficacy. 75 pts 
wer!! male, group mean age was 59.5 years (range 17- 
82) . Underlying heart disease was coronary artery 
disaase in 64 pts, 5 walvular, 2 hypertensive, 21 
carl$iomyopathy, 2 otter, 6 unknown. EPS protocol 
inc Luded up to 3 premature stimuli during 
sinus rhythm and ventricular pacing at 2 rates. 
\I=: AAD efficacy as assessed by EPS was 
t’irered in 808 of pts. Sustained VT was induced 
at xepeat EPS in 170 of pts during AAD therapy 
previously defined effective. 23 pts had 
confSrmation EPS on more than one AAD, 35% failed 
second AAD confirmation. FONCLUSIONS: 1) EPS 
results durirlg MD therapy exhibit y to day 
varide:bility. 2) Sustained VT can be induced during 
AAD therapy previously felt to be effective, 
3) Confirmtlon of naninducibility during AAD 
therapy in pts with VT is recommended. 
